| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Histone H4 (2-21) targets the N-terminal tail of histone H4, which is subject to various post-translational modifications including acetylation, methylation, phosphorylation, and ubiquitination. These modifications regulate chromatin structure, gene expression, DNA repair, and other chromatin-related processes. The peptide fragment is used as a substrate for histone-modifying enzymes, including histone acetyltransferases, histone deacetylases, and histone methyltransferases. By studying this peptide, researchers can investigate the role of histone H4 modifications in chromatin biology and epigenetics.
|
|---|---|
| ln Vitro |
In vitro studies on Histone H4 (2-21) are focused on its use as a substrate for histone-modifying enzymes. The peptide is used in enzyme activity assays to study histone acetyltransferases, histone deacetylases, histone methyltransferases, and other enzymes that modify histone H4. The compound's ability to mimic the N-terminal tail of histone H4 makes it valuable for studying the specificity and kinetics of these enzymes. The peptide is also used in binding studies to investigate interactions with histone-binding proteins and chromatin remodeling complexes.
|
| ln Vivo |
Cellular assays for Histone H4 (2-21) are not typically performed, as the peptide fragment is used primarily as a research tool for in vitro studies of histone-modifying enzymes. The peptide is not taken up by cells and is not used for cellular studies. Instead, it is used in biochemical assays to study the enzymatic activities and substrate specificities of histone-modifying enzymes.
|
| Enzyme Assay |
In vivo studies on Histone H4 (2-21) are not applicable, as the compound is a research tool used primarily for in vitro studies. The peptide fragment is not intended for therapeutic use and is not studied in animal models. Researchers use the compound to study histone modifications and chromatin biology in vitro.
|
| Cell Assay |
The in vitro enzyme assays for Histone H4 (2-21) typically involve measuring the activity of histone-modifying enzymes using the peptide as a substrate. In these assays, the peptide is incubated with the enzyme and cofactors, and the incorporation of modifications (e.g., acetylation, methylation) is measured using mass spectrometry, Western blotting with modification-specific antibodies, or radioactive labeling. The peptide's suitability as a substrate is assessed by comparing its modification to that of the full-length histone H4 protein. These assays are standard for characterizing histone-modifying enzymes.
|
| Animal Protocol |
Cellular assays for Histone H4 (2-21) are not performed, as the compound is a research tool used for in vitro studies. The peptide fragment is not used in cell-based assays and is not studied for its effects on cells.
|
| ADME/Pharmacokinetics |
In vivo animal studies for Histone H4 (2-21) are not applicable. The compound is a research tool used for in vitro studies of histone modifications and chromatin biology. It is not administered to animals.
|
| Toxicity/Toxicokinetics |
Histone H4 (2-21) has a molecular weight of approximately 2224.61 and a molecular formula of C100H166N34O29. The compound is a synthetic peptide and is typically stored as lyophilized powder at -20degC for long-term storage. The peptide is soluble in water and other appropriate buffers for biochemical assays. Detailed pharmacokinetic parameters are not applicable, as the compound is not a therapeutic agent.
|
| References | |
| Additional Infomation |
The Histone H4 (2-21) peptide fragment is a research tool and is not intended for therapeutic use. As a peptide fragment, it is not expected to have significant toxicity at the concentrations used in biochemical assays. Standard safety precautions should be followed when handling the compound, including the use of appropriate personal protective equipment. The compound is for research use only and not for human or veterinary use.
|
| Molecular Formula |
C82H150N36O22
|
|---|---|
| Molecular Weight |
1992.29641389847
|
| Exact Mass |
1991.172
|
| CAS # |
667899-73-2
|
| PubChem CID |
171689227
|
| Appearance |
White to off-white solid powder
|
| LogP |
-14.6
|
| Hydrogen Bond Donor Count |
37
|
| Hydrogen Bond Acceptor Count |
32
|
| Rotatable Bond Count |
79
|
| Heavy Atom Count |
140
|
| Complexity |
4010
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C(O)(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CO)N
|
| InChi Key |
RLPPOYIZNQZTDS-PWZLSCLCSA-N
|
| InChi Code |
InChI=1S/C82H150N36O22/c1-46(2)33-58(113-67(127)43-105-72(132)52(19-6-11-27-85)109-63(123)39-100-61(121)37-103-70(130)50(17-4-9-25-83)110-65(125)41-104-73(133)53(22-14-30-96-80(89)90)112-64(124)40-101-69(129)49(88)44-119)74(134)106-42-66(126)111-51(18-5-10-26-84)71(131)102-36-60(120)99-38-62(122)108-47(3)68(128)114-54(20-7-12-28-86)75(135)115-56(24-16-32-98-82(93)94)77(137)118-59(34-48-35-95-45-107-48)78(138)116-55(23-15-31-97-81(91)92)76(136)117-57(79(139)140)21-8-13-29-87/h35,45-47,49-59,119H,4-34,36-44,83-88H2,1-3H3,(H,95,107)(H,99,120)(H,100,121)(H,101,129)(H,102,131)(H,103,130)(H,104,133)(H,105,132)(H,106,134)(H,108,122)(H,109,123)(H,110,125)(H,111,126)(H,112,124)(H,113,127)(H,114,128)(H,115,135)(H,116,138)(H,117,136)(H,118,137)(H,139,140)(H4,89,90,96)(H4,91,92,97)(H4,93,94,98)/t47-,49-,50-,51-,52-,53-,54-,55+,56-,57-,58-,59-/m0/s1
|
| Chemical Name |
(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2S)-6-amino-2-[[2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]hexanoyl]amino]acetyl]amino]acetyl]amino]hexanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]acetyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~50.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (50.19 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5019 mL | 2.5097 mL | 5.0193 mL | |
| 5 mM | 0.1004 mL | 0.5019 mL | 1.0039 mL | |
| 10 mM | 0.0502 mL | 0.2510 mL | 0.5019 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
